- Record: found
- Abstract: found
- Article: not found
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.
Raanan Berger
1 ,
Rinat Rotem-Yehudar ,
Gideon Slama ,
Shimon Landes ,
Abraham Kneller ,
Merav Leiba ,
Maya Koren-Michowitz ,
Avichai Shimoni ,
Arnon Nagler
May 15 2008
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
CT-011 is a humanized IgG1 monoclonal antibody that modulates the immune response through interaction with PD-1, a protein belonging to the B7 receptor family present on lymphocytes. The objectives of this phase I study were to assess the dose-limiting toxicities, to determine the maximum tolerated dose, and to study the pharmacokinetics of CT-011 administered once to patients with advanced hematologic malignancies.